JP2024534804A5 - - Google Patents
Info
- Publication number
- JP2024534804A5 JP2024534804A5 JP2024510274A JP2024510274A JP2024534804A5 JP 2024534804 A5 JP2024534804 A5 JP 2024534804A5 JP 2024510274 A JP2024510274 A JP 2024510274A JP 2024510274 A JP2024510274 A JP 2024510274A JP 2024534804 A5 JP2024534804 A5 JP 2024534804A5
- Authority
- JP
- Japan
- Prior art keywords
- stereoisomer
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210108316 | 2021-08-17 | ||
| KR10-2021-0108316 | 2021-08-17 | ||
| PCT/KR2022/012254 WO2023022497A1 (ko) | 2021-08-17 | 2022-08-17 | Sos1 억제제 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534804A JP2024534804A (ja) | 2024-09-26 |
| JP2024534804A5 true JP2024534804A5 (cg-RX-API-DMAC7.html) | 2025-07-25 |
Family
ID=85239600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510274A Pending JP2024534804A (ja) | 2021-08-17 | 2022-08-17 | Sos1阻害剤及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240400518A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4389738A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534804A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230026288A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118119600A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022330732A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229566A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024000342A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310872A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002016A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20240879A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202328076A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023022497A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240127910A (ko) * | 2023-02-16 | 2024-08-23 | 주식회사 카나프테라퓨틱스 | Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물 |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025163050A1 (en) * | 2024-01-31 | 2025-08-07 | Les Laboratoires Servier | New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202602869A (zh) * | 2024-04-10 | 2026-01-16 | 法商施維雅藥廠 | 新醯胺衍生物、包含其之醫藥組合物及其作為sos1抑制劑之用途 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026038916A1 (ko) * | 2024-08-14 | 2026-02-19 | (주) 사이러스테라퓨틱스 | Sos1 억제 활성을 갖는 신규 화합물 |
| CN119431234A (zh) * | 2024-08-19 | 2025-02-14 | 中国药科大学 | 一种苄胺甲酰类化合物及其制备方法与应用 |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098352A2 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| BRPI0713187A2 (pt) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20110098324A1 (en) * | 2008-06-25 | 2011-04-28 | Brackley Iii James A | Prolyl hydroxylase inhibitors |
| JP5572725B2 (ja) * | 2010-03-10 | 2014-08-13 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎の処置のための化合物 |
| CN102558147B (zh) * | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | 化合物、制备方法及应用 |
| AR086113A1 (es) * | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
| MX2014012991A (es) * | 2012-04-24 | 2015-08-14 | Chugai Pharmaceutical Co Ltd | Derivado de benzamida. |
| WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| WO2014205594A1 (en) * | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
| EP3061747B1 (en) * | 2013-10-25 | 2021-04-07 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
| PL3728254T3 (pl) * | 2017-12-21 | 2023-06-12 | Boehringer Ingelheim International Gmbh | Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1 |
| WO2021028645A1 (en) * | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| PH12022551513A1 (en) * | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4472974A4 (en) * | 2022-02-04 | 2026-03-25 | Schroedinger Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
-
2022
- 2022-08-17 KR KR1020220102624A patent/KR20230026288A/ko active Pending
- 2022-08-17 TW TW111130992A patent/TW202328076A/zh unknown
- 2022-08-17 IL IL310872A patent/IL310872A/en unknown
- 2022-08-17 US US18/684,629 patent/US20240400518A1/en active Pending
- 2022-08-17 MX MX2024002016A patent/MX2024002016A/es unknown
- 2022-08-17 JP JP2024510274A patent/JP2024534804A/ja active Pending
- 2022-08-17 WO PCT/KR2022/012254 patent/WO2023022497A1/ko not_active Ceased
- 2022-08-17 CN CN202280069947.0A patent/CN118119600A/zh active Pending
- 2022-08-17 EP EP22858734.1A patent/EP4389738A4/en active Pending
- 2022-08-17 AU AU2022330732A patent/AU2022330732A1/en active Pending
- 2022-08-17 CA CA3229566A patent/CA3229566A1/en active Pending
- 2022-08-17 PE PE2024000267A patent/PE20240879A1/es unknown
-
2024
- 2024-02-02 CL CL2024000342A patent/CL2024000342A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7485810B2 (ja) | 癌を処置する方法 | |
| JP3397320B2 (ja) | 縮合イミダゾリウム誘導体 | |
| KR102381295B1 (ko) | {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도 | |
| AU2008267048B2 (en) | Azapeptide derivatives | |
| JP2023552610A5 (cg-RX-API-DMAC7.html) | ||
| TW202015698A (zh) | Tlr7/tlr8抑制劑之晶型 | |
| RU2011121876A (ru) | Пиразолопиримидиновые соединения-ингибиторы jak и способы | |
| CN105473573B (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
| CN112135827A (zh) | 盐、晶型及其制备方法 | |
| AU2007220419A1 (en) | Selective androgen receptor modulators | |
| JP2004516314A5 (cg-RX-API-DMAC7.html) | ||
| JP2021522262A5 (cg-RX-API-DMAC7.html) | ||
| SG11202110683WA (en) | Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof | |
| WO2017120124A1 (en) | Azetidine modulators of the sphingosine 1-phosphate receptor | |
| CN105026362B (zh) | 双环化合物 | |
| CN108778288A (zh) | 可用于治疗疾病的FimH的甘露糖衍生的拮抗剂 | |
| JP2021536505A5 (cg-RX-API-DMAC7.html) | ||
| JP2025511277A5 (cg-RX-API-DMAC7.html) | ||
| CN121889382A (zh) | Prmt5抑制剂及其制备方法 | |
| JP2025502712A5 (cg-RX-API-DMAC7.html) | ||
| JP2022549601A5 (cg-RX-API-DMAC7.html) | ||
| JP2025502497A (ja) | 3-[(ベンゾ[d][1,3]ジオキソラン-4-イル)オキシ]プロピルアミン塩酸塩およびその光学異性体、結晶、ならびに調製方法 | |
| JP2023547346A5 (cg-RX-API-DMAC7.html) | ||
| JP2021514347A (ja) | 抗rsv活性を有するシクロアルキル置換ピラゾロピリミジン | |
| KR20040034804A (ko) | 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물 |